MRZ
0.255
522%
AR1
0.048
-70%
NTM
0.004
100%
MAY
0.008
-46.7%
HIQ
0.023
53.3%
AQZ
1.45
-42.7%
SPX
0.003
50%
QXR
0.003
-40%
AMS
0.03
42.9%
DTI
0.014
-39.1%
TAS
0.027
42.1%
PIM
0.09
-37.9%
FRX
0.017
41.7%
ENT
0.004
-33.3%
XPN
0.017
41.7%
M2R
0.002
-33.3%
VBS
0.2
37.9%
AAJ
0.015
-31.8%
FBR
0.004
33.3%
TMG
0.105
-30%
FLC
0.135
28.6%
AKN
0.005
-28.6%
JGH
0.036
28.6%
AFA
0.072
-28%
OLL
0.05
28.2%
DM1
0.008
-27.3%
VBC
0.14
27.3%
ASM
0.665
-27.3%
ZNO
0.063
26%
LDX
0.175
-27.1%
ADR
0.005
25%
AHK
0.465
-26.8%
DDT
0.005
25%
ANG
0.195
-26.4%
MMR
0.005
25%
LSR
0.023
-25.8%
RKB
0.005
25%
DAL
0.035
-25.5%
ICR
0.022
22.2%
ICE
0.059
-25.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGN on track for Phase 2 trials during CY24

Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts